Across TCGA pan-cancer cohorts, AMD1 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of AMD1’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AMD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AMD1 is over-expressed in tumor.
CCRCC and LSCC are the cancer types where AMD1 tumor–normal differential expression is most reproducible.